Shire dodges pricing questions as lanadelumab’s big day nears

Takeda, whose stock has been battered since it expressed an interest in Shire, might finally get some good news in the next few weeks. The biggest pipeline prospect of its takeover target, the next-generation hereditary angioedema asset lanadelumab, is due an FDA approval decision by August 26.